U.S. Markets closed

Here's What Biogen Inc.'s (NASDAQ:BIIB) P/E Ratio Is Telling Us

Simply Wall St

Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card!

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we'll show how Biogen Inc.'s (NASDAQ:BIIB) P/E ratio could help you assess the value on offer. Biogen has a price to earnings ratio of 10.79, based on the last twelve months. That means that at current prices, buyers pay $10.79 for every $1 in trailing yearly profits.

See our latest analysis for Biogen

How Do You Calculate Biogen's P/E Ratio?

The formula for price to earnings is:

Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Or for Biogen:

P/E of 10.79 = $233.27 ÷ $21.62 (Based on the trailing twelve months to December 2018.)

Is A High P/E Ratio Good?

A higher P/E ratio means that investors are paying a higher price for each $1 of company earnings. That isn't necessarily good or bad, but a high P/E implies relatively high expectations of what a company can achieve in the future.

How Growth Rates Impact P/E Ratios

Companies that shrink earnings per share quickly will rapidly decrease the 'E' in the equation. Therefore, even if you pay a low multiple of earnings now, that multiple will become higher in the future. Then, a higher P/E might scare off shareholders, pushing the share price down.

Biogen increased earnings per share by a whopping 81% last year. And it has bolstered its earnings per share by 10% per year over the last five years. With that performance, I would expect it to have an above average P/E ratio.

How Does Biogen's P/E Ratio Compare To Its Peers?

The P/E ratio indicates whether the market has higher or lower expectations of a company. The image below shows that Biogen has a lower P/E than the average (19.7) P/E for companies in the biotechs industry.

NasdaqGS:BIIB Price Estimation Relative to Market, April 4th 2019

Biogen's P/E tells us that market participants think it will not fare as well as its peers in the same industry. Many investors like to buy stocks when the market is pessimistic about their prospects. It is arguably worth checking if insiders are buying shares, because that might imply they believe the stock is undervalued.

Remember: P/E Ratios Don't Consider The Balance Sheet

The 'Price' in P/E reflects the market capitalization of the company. In other words, it does not consider any debt or cash that the company may have on the balance sheet. Theoretically, a business can improve its earnings (and produce a lower P/E in the future), by taking on debt (or spending its remaining cash).

Such spending might be good or bad, overall, but the key point here is that you need to look at debt to understand the P/E ratio in context.

How Does Biogen's Debt Impact Its P/E Ratio?

Biogen's net debt is 5.2% of its market cap. The market might award it a higher P/E ratio if it had net cash, but its unlikely this low level of net borrowing is having a big impact on the P/E multiple.

The Verdict On Biogen's P/E Ratio

Biogen has a P/E of 10.8. That's below the average in the US market, which is 17.7. The company hasn't stretched its balance sheet, and earnings growth was good last year. If it continues to grow, then the current low P/E may prove to be unjustified. Given analysts are expecting further growth, one might have expected a higher P/E ratio. That may be worth further research.

When the market is wrong about a stock, it gives savvy investors an opportunity. As value investor Benjamin Graham famously said, 'In the short run, the market is a voting machine but in the long run, it is a weighing machine.' So this free visual report on analyst forecasts could hold the key to an excellent investment decision.

You might be able to find a better buy than Biogen. If you want a selection of possible winners, check out this free list of interesting companies that trade on a P/E below 20 (but have proven they can grow earnings).

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.